- Home
- EM vs IPHA Comparison
EM vs IPHA Comparison
Compare EM & IPHA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | EM | IPHA |
|---|---|---|
| Founded | 2017 | 1999 |
| Country | China | France |
| Employees | N/A | N/A |
| Industry | Other Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 291.6M | 174.2M |
| IPO Year | 2021 | 2019 |
Fundamental Metrics
Financial Performance| Metric | EM | IPHA |
|---|---|---|
| Price | $1.15 | $1.80 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 3 |
| Target Price | $1.25 | ★ $5.00 |
| AVG Volume (30 Days) | ★ 544.0K | 26.6K |
| Earning Date | 03-05-2026 | 09-17-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $259,541,587.00 | $14,839,695.00 |
| Revenue This Year | $3.30 | $22.29 |
| Revenue Next Year | $5.26 | $43.90 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.99 | $1.63 |
| 52 Week High | $1.46 | $2.63 |
Technical Indicators
Market Signals| Indicator | EM | IPHA |
|---|---|---|
| Relative Strength Index (RSI) | 34.99 | 49.79 |
| Support Level | $1.13 | $1.70 |
| Resistance Level | $1.19 | $1.86 |
| Average True Range (ATR) | 0.04 | 0.08 |
| MACD | 0.01 | 0.01 |
| Stochastic Oscillator | 78.93 | 56.25 |
Price Performance
Historical ComparisonAbout EM Smart Share Global Limited
Smart Share Global Ltd is a consumer tech company providing mobile device charging services through an extensive online and offline network in China. It provides service through power banks, placed in POIs operated by location partners, such as entertainment venues, restaurants, shopping centers, hotels, transportation hubs, and public spaces. Geographically, the company generates revenue from the PRC. The company has two segments, the mobile device charging segment and the PV business segment. The company generates the majority of its revenue from the mobile device charging segment.
About IPHA Innate Pharma S.A. ADS
Innate Pharma SA is a clinical-stage biotechnology company. It is engaged in developing immunotherapies for cancer patients. Its approach is to harness the innate immune system through therapeutic antibodies and its ANKET (Antibody-based NK cell Engager Therapeutics) proprietary platform. The company's revenue results from payments received to research, collaboration, and licensing agreements signed with pharmaceutical companies. Its product pipeline includes lacutamab, monalizumab, IPH5201, IPH5301, IPH6101, IPH62, IPH6401 and IPH6501.